`_____________________
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`_____________________
`
`
`
`AMNEAL PHARMACEUTICALS LLC and
`PAR PHARMACEUTICAL, INC.
`Petitioner
`
`v.
`
`JAZZ PHARMACEUTICALS, INC.
`Patent Owner
`
`
`
`_____________________
`
`CASE IPR2015-00547
`Patent 7,765,107
`_____________________
`
`
`PAR PHARMACEUTICAL, INC.’S UPDATED MANDATORY NOTICES
`PURSUANT TO 37 C.F.R. § 42.8(A)(3)
`
`
`
`Mail Stop “PATENT BOARD”
`Patent Trial and Appeal Board
`U.S. Patent and Trademark Office
`P.O. Box 1450
`Alexandria, VA 22313-1450
`
`
`
`Petitioner Par Pharmaceutical, Inc. (“Par”) is a real-party-in-interest for this
`
`IPR2015-00547
` Patent No. 7,765,107
`
`
`
`proceeding. Out of an abundance of caution, and as a result of ongoing integration
`
`and reorganization activities, Petitioner identifies the following additional entities
`
`as real-parties-in-interest who, going forward, may have control over this
`
`proceeding: Endo International PLC; Endo DAC; Endo Management Limited;
`
`Endo Luxembourg Holding Company S.a.r.l.; Endo Luxembourg Finance
`
`Company I S.a.r.l.; Endo U.S. Inc.; Endo US Holdings Luxembourg I S.a.r.l.; Endo
`
`US Holdings Luxembourg II S.a.r.l.; Endo Health Solutions Inc.; Hawk
`
`Acquisition Ireland Limited; and Par Pharmaceutical Companies, Inc.1
`
`
`1 Patent Owner Jazz Pharmaceuticals, Inc. has asserted that various entities,
`
`including Par Pharmaceutical Holdings, Inc., Sky Growth Intermediate Holdings
`
`Corporation I, Sky Growth Intermediate Holdings Corporation II and an entity
`
`named Par Pharmaceutical Companies, Inc., were improperly not named as real-
`
`parties-in-interest in their Preliminary Response (Paper No. 10). As a result of
`
`Endo International PLC’s acquisition of Par Pharmaceutical, Inc., Petitioner notes
`
`that Sky Growth Intermediate Holdings Corporation I, Sky Growth Intermediate
`
`Holdings Corporation II and Par Pharmaceutical Companies, Inc. were merged into
`
`and reorganized with Par Pharmaceutical Holdings, Inc., which was immediately
`
`thereafter re-named Par Pharmaceutical Companies, Inc. For clarity, the newly
`
`
`
`1
`
`
`
`
`
`
`
`
`
`
`
`
`
`Respectfully Submitted,
`
`IPR2015-00547
` Patent No. 7,765,107
`
`
`
`Date: October 21, 2015
`
`
`
`
`
`
`
`
`Matthew C. Ruedy (Reg. No. 64,823)
`MADDOX EDWARDS, P.L.L.C.
`1900 K Street NW – Suite 725
`Washington, D.C. 20006
`(202) 830-0779
`mruedy@meiplaw.com
`
`Attorney for Petitioners
`
`
`
`
`reorganized Par Pharmaceutical Companies, Inc. is not identical to the entity
`
`previously known by the same name.
`
`
`
`2
`
`
`
`CERTIFICATION OF SERVICE (37 C.F.R. §§ 42.6(e))
`
`IPR2015-00547
` Patent No. 7,765,107
`Certificate of Service
`
`
`The undersigned hereby certifies
`
`that
`
`the above-captioned “Par
`
`Pharmaceutical, Inc.’s Updated Mandatory Notices Pursuant to 37 C.F.R. §
`
`42.8(A)(3)” was served in its entirety on October 21, 2015 by filing these
`
`documents through the Patent Review Processing System, as well as e-mailing
`
`John V. Biernacki
`JONES DAY
`North Point
`901 Lakeside Avenue
`Cleveland, OH 44114
`jvbiernacki@jonesday.com
`
`copies to the following:
`
`F. Dominic Cerrito
`Eric C. Stops
`Gabriel P. Brier
`QUINN EMANUEL URQUHART &
`SULLIVAN LLP
`51 Madison Avenue
`22nd Floor
`New York, NY 10010
`nickcerrito@quinnemanuel.com
`
`
`
`
`Date: October 21, 2015
`
`
`
`
`
`
`
` Matthew C. Ruedy (Reg. No. 64,823)
`MADDOX EDWARDS, P.L.L.C.
`1900 K Street NW – Suite 725
`Washington, D.C. 20006
`(202) 830-0779
`mruedy@meiplaw.com
`
`Attorney for Petitioners
`
`
`
`1